News
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution 4D Molecular Therapeutics, Inc. Wed, Jul 2, 2025, 4:05 PM 7 min read ...
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback